Katja Hanack

Since decades selection of antibody producing hybridoma cells has been performed by limited dilution and numerous ELISA screenings in order to find suitable antibody-producing cells. These processes are very laborious, time-consuming and expensive. This dilemma motivated us to develop a new selection technology. We developed selma: selma is based on

We base our immunization strategy onto the most efficient danger signals to the mammalian immune system: viruses. By combining efficient surface-related epitopes with a viral particle system originated from the hamster polyomavirus, we are able to perform a hyper-immunization schedule, extraordinarily faster than conventional immunization strategies. In close cooperation with

With our in house developed in vitro immunisation process we are able to activate naive B lymphocytes antigen-specifically within 12 days and fuse them afterwards with our transgenic fusion cell line. As a result we can identify hybridoma clones producing antigen-specific human IgM or IgG immunoglobulins. For the selection of

For some applications conventional antibodies might not be suitable due to their size or the size of the requested antigen. Therefore, we offer the generation of recombinant camelid heavy-chain only antibodies. Those antibodies - highly stable and small in size - reveal a complete new spectrum of antigen-binding in the

Beside our customized antibody generation systems, we provide the genetic engineering of mammalian cells. Initially we optimize your sequence of interest with the help of bioinformatics tools e.g. Kozak consensus sequence. In use of a transposon related expression vector we stably insert your genes of interest and obtain transgenic